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Background: In developed countries, the use of Hib conjugate vaccines has led to the near disappearance of invasive 
Hib disease, but costs have limited its use in developing countries. In order to identify more economical vaccination 
schedules, we carried out a trial to evaluate the immunogenicity of an alternative two-dose PRP-T regimen, based 
on a previous report in which carrier priming could be obtained with prior diphtheria-tetanus-pertussis (DTP) 
vaccination. 
Methods: Healthy infants were enrolled to receive the PRP-T given at 3 and 5 months of age, with DTP vaccination 
given at 2,4 and 6 months of age. Serum specimens were obtained at 3,6 and 1.5 months of age. IgG anti-Hib titer 
determination was performed using enzyme-linked immunosorbent assay to evaluate serologic response and its 
duration. 
Results: One-hundred and seventeen infants were enrolled. The geometric mean titer (GMT) of antibody to PRP 
was low in the pre-immunization samples (0.13 ug/mL), achieving high values after two doses of PRP-T (27.42 
ug/mL), with all titers over 1 pg/mL; the GMT at 15 months was 5.45 ug/mL; 94.6% of infants had serologic responses 
after the two doses of vaccination, with average intervals of 27 and 22 days between DTP and PRP-T first-to-first 
and second-to-second administrations, respectively. However, these intervals were 11 and 3 days for infants who did 
not have serologic responses (P=O.O013 and 0.0030, respectively). 
Conclusions: These results indicate that two doses of PRP-T can induce high antibody titers using the proposed 
schedule; moreover, the GMT assessed at 15 months of age was also protective. The enhanced immune response 
observed in the study could be explained by the previous administration of the DTP vaccine, since the longer the 
interval between DTP and PRP-T, the better the response to Hib vaccine.The PRP-T vaccine given at 3 and 5 months 
of age may be an economical alternative to the current proposed schedule, which could make the introduction of 
Hib vaccination in developing countries more feasible, considering the relatively high cost of this vaccine. 
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INTRODUCTION 
The disease caused by Haemophilus injluenzae type b 
(Hib) has worldwide distribution. Until recently, Hib 
constituted the principal pathogen causing meningitis in 
the USA, with an attack rate of 47 cases/100 000 children 
younger than 5 years old, and an attack rate of 130 
cases/100 000 infants younger than 1 year old. On the 
other hand, the attack rate in Europe is approximately 
half that in the USA, with 20-30 cases/100 000 children 
younger than 5 years old.’ 
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However, in developing countries there are reports 
of higher incidences: Gambia has an incidence per year 
of 60 cases/100 000 children younger than 5 years old.’ 
In total, 6684 cases of Hib meningitis were reported 
to the Brazilian National Health Surveillance System 
between 1987 and 1991. Infants younger than 1 year 
old were mostly involved, with an attack rate of 17.7 
cases/100 000 inhabitants. Attack rate sharply decreased 
to 4.8000 000 at age l-4 years.2 Probably, these numbers 
do not correspond to reality, due to lack of information 
from the surveillance system and difficulty in making 
the accurate diagnosis. 
In the USA, only 40% of cases of Hib meningitis 
occur in children younger than 1 year of age, but in 
developing countries, 67-84% of cases of Hib meningitis 
occur in children younger than 1 year of age.’ 
An 11-year study of invasive Haemophilus infections 
in Sao Paulo, Brazil demonstrated that 48.6% of Hib 
infections were identified in children younger than 1 
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year of age, the median was 1 year of age, and the peak 
was observed at 7 months of age.3 
The mortality also ranged from 1% to 8% in 
developed countries, compared to 30% or more in 
developing countries, and permanent sequelae (e.g. hear- 
ing and mental deficiency) were observed in 20% of 
the survivors.4 In Brazil, the overall fatality rate of Hib 
meningitis was 15.9%.2 
These worldwide epidemiologic discrepancies and 
cost-effectiveness issues concerning Hib immunization 
reinforce the need to consider different vaccination 
schedule programs based on local epidemiologic data 
and economical standards. 
Anti-Hib conjugated vaccines were introduced into 
routine vaccinations in several countries after they were 
licensed in January 1991. Vaccines from different manu- 
facturers have provided significant reductions in the Hib 
attack rate worldwide.5 In the city of Curitiba, Brazil, 
there was a significant decrease in the attack rate of Hib 
meningitis in children younger than 5 years old after 
vaccination was started (from 35.4 cases/100 000 children 
in 1996 to 9.73 cases/100 000 in 1997).6 
Although a single dose of vaccine given at 15 months 
of age can induce protection, the central issue is how 
to protect younger infants, who are the main target of 
the disease, with less doses than the proposed four-dose 
schedule starting at 2 months of age. 
Different strategies have been tried to achieve 
this goal. In 1996, Chile became the second develop- 
ing country to introduce the vaccine anti-Hib in their 
calendar, exploring ways to lower the cost of vaccination 
without compromising immunization effectiveness. 
Comparing 627 children allocated to receive one of the 
four proposed schedules-three full doses; three one- 
half doses; three one-third doses; and two full doses- 
Lagos et al concluded that all the schedules resulted in 
an appropriate serologic response, and the fractional 
doses (half or a third) were able to induce appropriate 
serum concentrations of antibodies (>0.15 ug/mL) in 
91-100% of immunized infants. This rate was similar to 
the 93% rate achieved with three full doses.’ 
The PRP-T vaccine is highly immunogenic in adults, 
infants and children older than 2 months of age.8 
Although the immune response in children is correlated 
with age, one to three doses are required to induce high 
titers of antibodies in children younger than 6 months 
of age. Serum titers over 1 ug/mL are considered pro- 
tective,9 and the estimated level of 0.15 ug/mL is now 
generally accepted. lo These antibodies can be passively 
acquired through maternal-fetal transmission, or, in the 
postpartum period, through natural exposure to Hib or 
specific immunization. 
In a study by Hessel et al, where children were 
immunized at 3,4 and 5 months of age, the geometric 
mean titers (GMTs) of anti-Hib were 6.8 ug/mL at 5 
months of age and 8.8 ug/mL at 6 months of age.” 
Recent studies in the USA, Finland and France showed 
GMTs of antibodies of 6-10 yg/mL in children im- 
munized with three doses during the initial 6 months of 
life.i2 
Since October 1992, PRP-T has been used in a pro- 
gram of accelerated immunization that consists of three 
doses at 2,3 and 4 months of age in the UK, or two doses 
at 4 and 6 months of age in Ireland.i3 These immuniza- 
tion schedules do not use boosters, because if the children 
are protected, a natural booster would occur without 
risk of developing disease. Moreover, previous vaccina- 
tion with DT or diphtheria-tetanus-pertussis (DTP) 
enhanced the magnitude of the response of anti-PRP to 
this conjugated vaccine.i4 
Hib vaccination has now been introduced into the 
routine Brazilian vaccination program,15 which fosters 
the evaluation of new, cost-effective immunization 
approaches. We conducted this study to evaluate the 
antibody response against Hib using a two-dose schedule 
of PRP-T at 3 and 5 months of age. The age group 
chosen for vaccination was based on the following: (1) 
the epidemiologic need for early protection; (2) know- 
ledge of the priming effect of the tetanus toxoid, the 
carrier protein in the PRP-T, providing a better response 
to anti-PRP; and (3) the tetanus toxoid is in fact 
routinely administered at 2, 4 and 6 months of age, 
through the vaccine DTP.i6 We chose an age group for 
anti-Hib vaccination such that the vaccine DTP had 
already been received. 
MATERIALS AND METHODS 
Patients and eligibility 
We enrolled 127 children who received primary care at 
the Section of Vaccination of the Hospital do Servidor 
Pdblico Estadual de Sao Paulo and who were eligible to 
participate. We obtained parents’ or legally responsible 
guardians’ informed consent. Exclusion criteria included 
known immunologic disorders or previous history of 
anti-Hib vaccination. 
Vaccine 
The vaccine used in this study was PRP-T (ActHIB, 
Pasteur Merieux) given in a dose of 0.5 mL intramus- 
cularly in the anterolateral part of the thigh. 
Immunization schedule 
The immunization schedule used was a regimen with 
two doses given at 3 and 5 months of age without 
booster (with a tolerance of 15 days after 3 or 5 months 
of age). 
The use of a small number of doses was decided 
upon to investigate the possibility of a reduction in costs. 
However, since the results of the serologic assays were 
not readly available, a booster was applied at 15 months 
of age without follow-up. 
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Blood samples and Hib serology 
Venous blood samples were collected, separated and 
stored at -20°C until the assays. These samples were 
collected in three time-points: (1) before immunization; 
(2) at 6 months of age; and (3) at 15 months of age (with 
a tolerance of 30 days after 6 or 15 months of age), 
in order to evaluate the seroconversion rate and the 
duration of the acquired immunity (Figure 1). 
IgG anti-Haemophilus influenzae type b polysac- 
charide was determined by an enzyme-linked immuno- 
sorbent assay (ELISA) employing microplates (Cova 
Link NH, Nunc) for antigen adsorption, as described by 
Zielen et a1,i7 with some modifications. Briefly, at the 
time of assay, 5 mg/L unconjugated Hib PRP was diluted 
with 1% 1-ethyl-3-(3-dimethyl aminopropyl) carbo- 
diimide (Sigma, USES) and incubated in the wells over- 
night at 37°C. After washing with phosphate-buffered 
saline (PBS)-O.OS% Tween, the serum samples were 
incubated in four serial dilutions for 2 h at 37°C. After 
washing with PBS-Tween, HRPO-conjugated anti-IgG 
(Sigma, USA) diluted 1 : 3000 was added to the plates, 
which were incubated for 90 min at 37°C. After washing, 
the substrate solution containing 0.4 mg orthophenylene- 
diamine and 0.01% a final concentration of Hz02 in 0.1 
M citrate-phosphate buffer was added. After 30 min at 
room temperature, the color reaction was stopped by 
the addition of 2.5 N H2S04, The absorbances were read 
in the plate reader (Flow, USA). 
Statistical analysis 
The results were analyzed using Epi Info version 5.1.b 
(Centers for Disease Control and Prevention-World 
Health Organization) and Microsoft Excel version 5.0 
software. Stastically significant differences were con- 
sidered for PcO.05. 
RESULTS 
One hundred and twenty-seven children were enrolled 
in the study. Ten children were excluded from the analy- 
sis for the following reasons: three children had just 
received the first dose of the vaccine anti-Hib, and seven 
children did not have serologic follow-up. The final 
number was therefore 117. 
012;45; 
Seventy-one children were male (60.6%) and forty- 
six were female (39.4%). 
Serology 
The GMTs pre-immunization were available for 115 
children; 7 (6.1%) had titers over 1.0 ug/mL, and the 
average was 0.13 yg/mL. 
GMTs after the second dose of the vaccine anti-Hib 
and at 15 months of age were, respectively, 27.42 ug/mL 
and 5.45 yg/mL (Table 1). 
While 93.9% of children were considered susceptible 
to Hib prior to vaccination, because they had titers of 
antibodies lower than 1.0 ug/mL, after vaccination with 
two doses, 94.6% of children had documented sero- 
conversion. At 15 months of age, 80% of children still 
had protecting titers of anti-Hib, as shown in Table 2. 
Interval between the doses of DTP and PRP-T 
The interval between the first dose of vaccine DTP and 
the first dose of vaccine anti-Hib was, on average, 27 
days. For second doses, this interval was, on average, 22 
Table 1. Geometric mean titer of anti-Hib antibodies prior to 
immunization, at 6 and 15 months of age 
GMT (95% Cl) 
Prior to immunization (N= 115 ) 0.13 pg/mL (0.02-2.2) 
At 6 months of age (N= 111) 27.42 pg/mL (13.1-156.1) 
At 15 months of age (N=lOO) 5.45 pg/mL (2.3-58.1) 
Table 2. Percentage of children with protecting antibody 
titers who received the anti-Hib vaccination with two doses 
of PRP-T 
Anti-Hib antibodies 
N >O. 15 pglml >l.Opglml 
Prior to 
vaccination 115 40% (N=46) 6.1% (N=7) 
At 6 months 
of age 111 98.1% (N=109) 94.6% (N=105) 
At 15 months 
of age 100 93% (N=93) 80% (N=80) 
* 
15 Months 
Figure 1. Vaccination and sample collection schedule. 
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Table 3. Averages of days between the vaccines DTP and PRP-T 
compared to seroconversion to Hib 
Seroconversion (+) 
6 months (N= 105) 
Seroconversion (-) 
6 months (N=6) 
Average of Average of 
interval interval 
between the between the 
first doses second doses 
(days) fdays) 
27 22 
11 3 
P 
Seroconversion (+) 
15 months (N=80) 
Seroconversion (-) 
15 months (N=20) 
0.0013 0.0030 
27 23 
22 15 
P 0.12 0.03 
days. Comparing the average intervals in children who 
presented seroconversion with those in children who did 
not respond to vaccine anti-Hib, we observed that, the 
longer the interval between DTP and PRP-T, the better 
the response to Hib vaccine (Table 3). 
DISCUSSION 
The capsular polysaccharide constitutes a major virulence 
factor of Hib. PRP conjugated vaccines are able to 
stimulate an appropriate immune response in infants, 
inducing protective antibodies against PRP of the 
bacteria.18 Several studies have demonstrated the 
safety and the immunogenicity of the PRP-T vaccine.” 
These studies, mostly conducted in developed countries, 
adopted a three-dose schedule. 
England and Ireland initiated immunization pro- 
grams in early infancy, where the incidence of invasive 
disease has a substantial peak,2O without booster doses, 
aiming early protection. On the other hand, some studies 
in Latin America have suggested that carrier priming 
with DTP can make the schedule with two doses an 
acceptable alternative to the standard regimen.7 Our 
results agree with this hypothesis, because only two 
doses of the PRP-T vaccine were able to induce high 
and durable titers of antibodies. 
The high titers of antibodies after the complete 
immunization were surprising. Recent studies of the 
PRP-T vaccine in children in the USA, Europe and 
Chile demonstrated anti-PRP GMTs ranging from 3.7 to 
11.3 ug/mL. 21-23 However, the GMT in our study was 
substantially higher (27.42 ug/mL). 
A possible explanation for this finding is that the 
vaccines DTP and PRP-T have been applied at different 
time points. The administration of the DTP on average 
25 days before the vaccine PRP-T may have resulted in 
a carrier priming phenomenon. Granoff et al demon- 
strated that infants vaccinated with DT at 1 month of 
age and subsequently vaccinated with PRP-T at 2,4 and 
6 months of age had their immune response increased 
threefold (GMT=11.5 ug/mL) when compared to 
infants who were not primed with DT.r4 These authors 
suggested that priming can be useful to accelerate 
acquisition of immunity to Hib in children younger than 
6 months of age, who are at the age of maximum risk for 
Hib disease. 
This priming also explains the high titers found in 
Venezuelan children vaccinated with PRP-T at 2,4 and 6 
months of age preceded by DTP vaccine by, on average, 
6.5 days. The anti-PRP GMT was 37.9 ug/mL, whereas 
that of children vaccinated simultaneously with DTP 
and PRP-T was 3.63 ug/mL (P<0.00001).24 
However, in our study, it is possible that the higher 
antibody titers reflect a longer interval between the 
priming with DTP and PRP-T vaccination. The statis- 
tically significant differences demonstrate that previous 
vaccination with DTP with a longer interval of time can 
enhance the immune response to Hib, when the vaccine 
PRP-T is used. 
Other explanations should be considered, such as 
genetic factors and possible natural exposure. 
Therefore, the vaccine anti-Hib with PRP-T given at 
3 and 5 months of age, in addition to DTP vaccination at 
2, 4 and 6 months of age, may constitute a safe and 
feasible alternative for introduction into the immuniza- 
tion program, with costs substantially lower, despite two 
extra visits to the immunization center. Although we have 
created a complex vaccine schedule, interposing 3- and 5- 
month doses of PRP-T between the 2-, 4- and 6-month 
doses of DTP without measuring compliance and indirect 
costs, we believe that this schedule makes sense when 
earlier protection (5 months versus 6 months) is desirable, 
given the local epidemiology. An alternative dosing 
schedule might have been 4 and 6 months. This would 
allow sufficient time following the infant tetanus priming 
dose and would minimize the number of immunization 
visits and associated costs. Further studies would be 
helpful to find more about the actual month-specific 
incidence of disease caused by Hib in this population. 
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